Abridged Audited Consolidated Financial Statements For The Fourteen Months Ended 28 February 2017 GO LIFE INTERNATIONAL LIMITED (Incorporated in the Republic of Mauritius) (Registration number: 098177 C1/GBL) Primary Listing SEM share code: GOLI.N0000 Secondary Listing JSE share code: GLI ISIN: MU0330N00004 (“the Company” or “Go Life International”) Abridged Audited Consolidated Financial Statements For The Fourteen Months Ended 28 February 2017 DIRECTORS’ COMMENTARY The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Category 1 Global Business License (License No - C110009034) issued by the Mauritius Financial Services Commission. Go Life International is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius (SEM) on 07 July 2011. The Company was previously structured as a PCC under the PCC Act and was converted into a limited company and changed its name to Go Life International Limited by way of a shareholder resolution on 31 March 2015. The name change was approved on 16 June 2015 in anticipation of the inward listing on the Alternative Exchange (“AltX”) of the Johannesburg Stock Exchange (“JSE”) and the conversion to a limited company became effective on 03 June 2016. PRIMARY OBJECTIVE Go Life International was established to leverage the strength of existing South African nutraceutical companies, Go Life Health Products and Gotha Health Products (collectively Go Life SA), and to drive the presence of the South African products and brands across the global nutraceutical market. Go Life product range prides itself on its natural products and supplements originated in the womb of Africa which are scientifically developed for the world and enhanced through unique technology. After the secondary listing on the AltX, new opportunities and strategic partners have come into being which have now positioned Go Life International to be a full-fledged medical and healthcare services company. COMPANY OUTLOOK The Company successfully completed a secondary listing on the AltX 23 November 2016. During 2016, the Company increased its shareholding in Go Life Health Products from 22% (directly held) to 100% (78% indirectly held through its wholly-owned subsidiary, Go Life Global). Go Life Health Products holds 100% of Gotha Health Products. Go Life also finalized the acquisition of Bon Health Frail care (100%) and Bon Health Properties (100%) and 49% of Bon Health Operations. Bon Health has a frail care and retirement village focus which also includes Alzheimer’s and dementia centres. There is an international need for such facilities and Bon Health has a highly effective and successful reputation and knowledge in managing such facilities. On the 22nd of February 2017 the Company signed an agreement with Elysium Healthcare Africa, giving the Company exclusive access to a full range of health products, generic medicines, services and equipment; and also to 25 countries in which Elysium Healthcare Africa has access. The Company hereby wishes to inform the general public that it has rescinded the appointment of Mr Oliver Bernhardt as a director of the Company. Mr Bernhardt formally accepted directorship in the Company, however, he failed to complete the necessary statutory documentation for filing. His inaction was not in the interest of the shareholders and consequently his appointment has been rescinded. CHANGE OF AUDITOR’S Grant Thornton resigned as auditors on 1 September 2017 and has advised that in accordance with Section 203 of the Mauritius Companies Act 2001, there are no circumstances connected with their resignation which should be brought to the attention of the Shareholders or creditors of the Company. Go Life International then appointed Aejaz Nazir Associates & Co on 11 September 2017 whom completed the audit. DIVIDENDS No dividends were authorized or paid during the period under review. By order of the Board AceTer Global Limited Company Secretary 03 October 2017 STATEMENT OF FINANCIAL POSITION THE THE GROUP GROUP THE COMPANY THE COMPANY 28 Feb 2017 31 Dec 2015 28 Feb 17 31 Dec 2015 USD USD USD USD ASSETS Non - Current Assets 36 517 190 1 418 242 34 851 774 1 418 242 Investments in Associates/Subsidiary 849 095 1 418 242 34 851 774 1 418 242 Intangible Assets 28 857 769 - - - Property Plant and Machinery 6 810 326 - - - Current Assets 638 321 7 875 402 7 875 Inventories 105 035 - - - Trade and other Receivables 144 085 5 947 312 5 947 Cash and Cash Equivalents 382 798 1 928 90 1 928 Income taxes 6 402 - - - TOTAL ASSETS 37 155 510 1 426 117 34 852 176 1 426 117 EQUITY Capital and Reserves 33 937 521 1 385 835 34 789 050 1 385 835 Share Capital 34 965 300 9 665 100 34 965 300 9 665 100 Revenue Deficit (1 027 779) (8 279 265) (176 250) (8 279 265) LIABILITIES Non - Current Liabilities 2 988 122 - - - Loan - Shareholders 2 988 122 - - - Current Liabilities 229 867 40 282 63 126 40 282 Trade and other Payables 229 867 40 282 63 126 40 282 TOTAL EQUITY AND LIABILITIES 37 155 510 1 426 117 34 852 176 1 426 117 STATEMENT OF CASH FLOWS THE THE GROUP GROUP THE COMPANY THE COMPANY 28 Feb 2017 31 Dec 2015 28 Feb 17 31 Dec 2015 USD USD USD USD Profit/ Loss for the year 30 325 122 292 (30 317) 122 292 Depreciation 8 105 - - - Other payables written back - (239 520) - (239 520) Receivables written off - 96 260 - 96 260 Share of profit/ loss of associate - (28 408) - (28 408) Net Cash from Operating activities (6 373 663) (49 376) (30 317) (49 376) Net Cash (used in) Financing activities - - - - Consolidation adjustment (6 373 663) - - - Net movement before working capital changes (6 335 232) (49 376) (30 317) (49 376) Inventories (105 036) - - - Trade and other receivables (144 085) (3 038) 5 635 (3 038) Trade and other payables 229 867 53 342 22 845 53 342 Net Cash from other operating activities (6 354 486) 928 (1 837) 928 Investing activities Property, plant and equipment 2 634 987 Movement in net cash resources (3 710 499) 928 (1 837) 928 Balance at the start of the year 4 093 297 1 000 1 928 1 000 Balance at the end of the year 382 798 1 928 91 1 928 PROFIT / LOSS AND OTHER COMPREHENSIVE INCOME THE THE THE THE GROUP GROUP COMPANY COMPANY 28 Feb 2017 31 Dec 2015 28 Feb 17 3 1 Dec 2015 USD USD USD USD Revenue 1 404 637 - 44 - Expenses (1 169 783) (49 376) (58 107) (49 376) PROFIT/ (LOSS) FROM OPERATIONS 234 854 (49 376) (58 063) (49 376) Share of profits - Associates 51 466 28 408 - 28 408 Other payables written back 27 746 239 520 27 746 239 520 Receivables written off - (96 260) - (96 260) 314 066 122 292 (30 317) 122 292 Finance costs (283 741) - - - PROFIT / (LOSS) BEFORE TAXATION 30 326 - (30 317) 122 292 Taxation (8 277) - - - TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 22 048 122 292 (30 317) 122 292 SEGMENTAL REPORTING – 14 MONTHS ENDED 28 FEB 2017 Please note: This is the first year of segmental reporting Frail care Nutraceutical Property Total Associate USD USD USD USD Statement of net profit/loss Revenue 1 017 557 335 614 51 466 1 404 637 Interest expenses - (71 064) - (71 064) Income Tax (8 277) - - (8 277) Adjusted Headline earnings (293 968) 264 550 51 466 22 048 Net profit/(loss) for the period Statement of financial position Total Assets 29 496 089 6 810 326 849 095 37 155 510 Total Borrowings - (2 988 122) - (2 988 122) RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS THE GROUP THE GROUP 28 Feb 17 31 Dec 2015 USD USD Basic earnings 22 048 122 292 Headline earnings 22 048 122 292 Adjusted headline earnings / Distributable earnings 22 048 122 292 Weighted average number of shares 613 089 321 96 650 100 Basic and diluted earnings per share (USD cents) 0.0036 0.13 Basic and diluted headline earnings per share (USD cents) 0.0036 0.13 Adjusted headline earnings per share (USD cents) 0.0036 0.13 STATEMENT OF CHANGES IN EQUITY Stated Revenue Total THE GROUP Capital Deficit Equity USD USD USD Consolidation adjustment on acquisition of investment 34 965 300 - 34 965 300 Total Comprehensive Income for the period - 22 048 22 048 Consolidation adjustments (1 049 827) (1 049 827) Balance as at 28 February 2017 34 965 300 (1 027 779) 33 937 521 Stated Translation Revenue Total THE COMPANY capital Reserve Deficit Equity USD USD USD USD Balance as at 01 January 2016 9 665 100 (524 751) (7 876 806) 1 263 543 Total Comprehensive Income for the period - - 122 292 122 292 Share Capital Issued 25 300 200 - - - Reclassification adjustment - 524 751 (524 751) - Balance as at 31 Dec 2016 34 956 300 - (8 279 265) 1 385 835 Balance as at 01 January 2017 34 965 300 - (8 279 265) 1 385 835 Total Comprehensive Income for the period - - (30 317) (30 317) Share of loss of associate written back - - 8 133 332 8 133 332 Balance as at 28 February 2017 34 965 300 - (176 250) 9 488 850 Notes The Company is required to publish financial results for the 14 months ended 28 February 2017 in terms of the Listing Rule 12.19 of the SEM. The abridged audited consolidated financial statements for the 14 months ended 28 February 2017 (“financial statements”) have been audited by Aejaz Nazir Associates & Co in accordance with the measurement and recognition requirements of IFRS, the requirements of IAS 34: Interim Financial Reporting and the SEM Listing Rules and the JSE Listing requirements. The accounting policies adopted in the preparation of the financial statements are consistent with those applied in the preparation of the audited financial statements of the year ended 31 December 2015. The prior year comparative results are for the company only as this is the first year operating as a group. Copies of the Abridged Audited Consolidated Financial Statements For The Fourteen Months Ended 28 February 2017 and the Statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the Company Secretary at the Registered Office of the Company at Beau Plan business Park, Pamplemousses 21001, Mauritius. This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.20 and section 88 of the Securities Act of Mauritius 2005. The Board accepts full responsibility for the accuracy of the information contained in these financial statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 28 February 2017 that require any additional disclosure or adjustment to the financial statement. For further information please contact: AceTer Global Limited (230) 204 080 Arbor Capital Sponsors +27 (0) 11 480 8500 SPONSOR Arbor Capital Sponsors Proprietary Limited Date: 03/10/2017 03:54:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.